Saudi Pharmaceutical Journal (Feb 2021)

Cancer Management in Saudi Arabia: Recommendations by the Saudi Oncology HeAlth Economics ExpeRt GrouP (SHARP)

  • Nora Alkhudair,
  • Majed Alshamrani,
  • Hadeel Samarkandi,
  • Hajer Almodaheem,
  • Hana Alabdulkarim,
  • Mai Alsaqaaby,
  • Fouad Alnajjar,
  • Hashem Alhashem,
  • Mohammed Bakkar,
  • Shouki Bazarbashi,
  • Mohammed Alnahedh,
  • Feras Alfraih,
  • Mohammad Alawagi,
  • Ahmed Al-jedai

Journal volume & issue
Vol. 29, no. 2
pp. 115 – 120

Abstract

Read online

Cancer is widely recognized as a major global health problem and is estimated to rank as one of the leading causes of death worldwide. Saudi Arabia has undergone remarkable socioeconomic development in the past 40 years which has contributed to the increase in cancer incidence. The high costs of new oncology medications in combination with uncertainty of long-term effectiveness and safety outcomes highlight the importance of considering value, in terms of clinical outcomes, relative to cost. We convened a group of experts to discuss key factors impacting the current state of cancer management in Saudi Arabia and to agree on a list of recommendations, with a focus on value-based care, considering evidence, patients, and costs.

Keywords